Skip to content


    DEA Class; Rx

    Common Brand Names; Rifamate (DSC)

    • Antitubercular Agents

    Oral combination antitubercular agent
    Used to treat pulmonary tuberculosis in patients already receiving a fixed dosage regimen; simplified regimen may promote adherence
    Monitor liver enzymes due to potential fatal hepatitis and hepatic dysfunction

    Indicated for pulmonary tuberculosis in which organisms are susceptible, and when the patient has been titrated on the individual components and it has therefore been established that this fixed dosage is therapeutically effective

    Hypersensitivity to isoniazid, rifamycins

    Acute liver disease, severe hepatic damage, acute gout

    Rifampin is contraindicated in patients receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity

    Rifampin is contraindicated with many drugs that are substrates of CYP, particularly CYP3A4

    Rifampin coadministration in patients receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir may substantially decrease plasma concentrations which may result in loss of antiviral efficacy for HIV infection and/or development of viral resistance

    History of diabetes mellitus (may make diabetes management more difficult)

    Rifampin is not recommended for intermittent therapy; caution patient against intentional or accidental interruption of daily dosage regimen since rare renal hypersensitivity reactions have been reported when therapy was resumed in such cases

    Rifampin has enzyme induction properties that can enhance the metabolism of endogenous substrates including adrenal hormones, thyroid hormones, and vitamin D

    No adequate and well-controlled studies have been performed in pregnant women; has been shown to be teratogenic in rodents

    Because of potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother


    2 capsules/day PO.


    2 capsules/day PO.


    15 to 17 years: 2 capsules/day PO.
    13 to 14 years: Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.



    • 300mg/150mg